to produce mature lamin A. 9 These modification steps are critical because the mutation carried by patients with HGPS prevents cleavage and thus lamin A maturation, resulting in the development of premature aging, including premature atherosclerosis/arteriosclerosis, characterized by VSMC degeneration and calcification, [10] [11] [12] and leading to vascular stiffness and myocardial infarction or stroke at an average age of 13 years. 8, [13] [14] [15] [16] In both human and animal studies, prelamin A accumulation has been shown to occur selectively in the vasculature, and prelamin A-induced VSMC calcification and senescence are reiterated in animal models of HGPS and in vascular cells differentiated from induced pluripotent stem cells derived from patients with HGPS. [17] [18] [19] [20] The mechanisms leading to premature aging and associated pathological changes are poorly understood; however, prelamin A has been shown to interfere with DNA damage repair signaling, leading to premature cell senescence. 21 It has also been shown to induce gene expression changes that perturb both Wnt and Notch signaling, as well as extracellular matrix production, to affect VSMC phenotype. 20, 22 Significantly, recent studies have also defined a role for prelamin A accumulation in the vascular degeneration observed in aged and atherosclerotic patients within the general population. 4, 5 Increased prelamin A accumulation was observed in atherosclerotic arteries, where it colocalized with senescent and calcifying VSMCs, and in medial VSMCs of aged patients with Mönckeberg sclerosis. 4, 23 Prelamin A also accumulates in VSMCs with increasing cell passage number in vitro concommitantly with decreased levels of its processing enzyme farnesylated proteins-converting enzyme 1 and increased levels of DNA damage. 4 Moreover, prelamin A expression in VSMCs was found to increase DNA damage and to promote premature senescence, suggesting a causal link between its accumulation and accelerated VSMC aging. 4 Interestingly, previous studies have shown that senescent VSMCs exhibit increased expression of the osteogenic markers alkaline phosphatase (ALP) and Runx2 24 and may have an enhanced susceptibility to calcification, indicating that VSMCs might adopt a specific calcifying phenotype during senescence/ aging. However, the mechanisms leading to this phenotype have not been explored. Given the associations between VSMC aging, calcification, and prelamin A accumulation, we investigated the mechanisms of age-induced VSMC osteogenic differentiation and define a major role for prelamin A accumulation and the DNA damage response (DDR) in this process.
Methods
Detailed Methods are provided in the Online Data Supplement.
Calcification Assays
Human aortic VSMCs from n=5 isolates were carefully characterized for proliferative capacity and used at early passages (passages 5-10), except when experiments required serial passaging to senescence. To induce mineralization, VSMCs were cultured in osteogenic media; M199 with 20% fetal bovine serum supplemented with calcium (2.7 mmol/L) and phosphate (2 mmol/L). 25 Calcification was visualized after fixation with 4% formaldehyde using Alizarin red (2%, wt/ vol, pH 4.2) and quantified by 45 Ca (≈50 000 cpm/mL) incorporation or spectrophotometrically with cresolphthalein, as previously described. 25 Von Kossa staining was used to detect calcium deposition in the vessel wall, as previously described. 26 ALP activity was determined as previously described. 25 Results are presented as fold change compared with control using data from 3 independent experiments.
Microarray Analysis
GeneChip Human Gene 1.0 ST Array (901417, Affymetrix) was used, which interrogates 28 869 well-annotated genes with 764 888 distinct probes. Complementary DNA synthesis, cRNA synthesis, and labeling were performed as described in the Affymetrix GeneChip Expression Analysis Technical Manual. Raw gene expression profiles were processed using Robust Multi-array Average. Affymetrix probe identifiers were mapped to their corresponding Entrez gene identifiers; probe sets with low variances across all arrays were removed; and in cases when multiple probes mapped to the same Entrez identifier, average expression was retained. Differentially expressed genes were identified using the limma 27 package, and raw P values were adjusted using the Benjamini-Hochberg correction. Genes with adjusted values of P<0.05 were considered to be significant. Pathway activity scores were generated by mapping all differentially expressed genes to curated biological pathways obtained from the Molecular Signatures Database (MSigDB version 3.0) 28 and calculating average t values of all mapped genes for each pathway. 29 Pathways with at least 5 differentially expressed genes were considered for analysis.
Cytokine Arrays
Conditioned medium (OPTI MEM, serum free, catalog No. 11058, GIBCO) from VSMCs was harvested after 3 days, filtered (0.2-mm pore), and analyzed using antibody arrays (RayBio, human cytokine antibody array VI and VII, catalog No. AAH-CYT-6/-7), according to manufacturer's instructions. Scanned images were read using PDQuest 2-D Analysis software (Bio-Rad). Protein intensities were determined by taking the average of the 2 spots specific to each protein, and all protein intensities on a given array were normalized against the BLANK, negative control (NEG), and positive control (POS) spots to allow comparison between arrays.
Clinical Studies
Medium-sized muscular arteries routinely removed and discarded in the course of planned surgery were collected from patients on dialysis at the time of dialysis catheter insertion or renal transplantation and compared with disease-free age-matched children (controls) undergoing intra-abdominal surgery at Great Ormond Street Hospital, London, with appropriate ethical approval (Online Table I ). Vessel rings were paraffin embedded, and immunohistochemistry and quantification of prelamin A-positive cells and calcium accumulation were performed, as previously described. 4, 26 
Statistical Analysis
Results are presented as mean±SEM. Within-group comparisons of continuous variables were performed using the paired t test for continuous variables and χ 2 test for categorical variables. For multiple comparisons, ANOVA and Newman-Keuls multiple-comparison test were performed. P<0.05 was considered significant. Statistical analyses were performed with GraphPad software. 
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Results
Prelamin A Accumulates in Calcifying VSMCs In Vivo and In Vitro
Previous studies demonstrated that prelamin A accumulated in calcified arteries of aged patients with atherosclerosis and Mönckeberg sclerosis. 4 To investigate whether prelamin A accumulates in calcified arteries regardless of age, we examined the arteries from young children on dialysis who develop hallmarks of premature vascular aging, including arterial stiffening, VSMC loss, and medial vascular calcification (Online Table I ). 26, 30 Prelamin A was heavily deposited in VSMCs in calcified arteries and localized to VSMC nuclei and medial cystic areas associated with dead or degenerate VSMCs, a pattern reminiscent of that observed in calcified arteries of old patients. 4 In contrast, prelamin A was not abundant in the arteries of control patients and was found to be localized to a polar area of the nucleus in a small subpopulation of contractile medial VSMCs ( Figure 1A and 1B).
The above study suggested that prelamin A deposition occurs in calcified arteries regardless of chronological age; therefore, we next examined whether there was a direct association between prelamin A accumulation and calcification in vitro. Primary human aortic VSMCs maintained in confluent culture spontaneously form a distinct hills-andvalleys morphology and form isolated nodules that undergo calcification. 23, 31 Immunostaining showed that these nodular VSMCs accumulated nuclear prelamin A ( Figure 1C ), and this accumulation was confirmed by Western blot, which showed no detectable prelamin A in proliferating VSMCs, whereas in mineralized VSMCs, there were increased levels of prelamin A in nodular areas compared with the monolayer ( Figure 1D ). Calcifying nodular VSMCs were also found to have elevated levels of p16 and increased staining for senescence-associated β-galactosidase compared with monolayer VSMCs ( Figure 1E and 1F), confirming a link between prelamin A accumulation, calcification, and senescence.
VSMCs Accumulate Prelamin A and Adopt an Osteoblastic Phenotype During In Vitro Aging
To determine whether VSMC osteogenic differentiation coincided with the accumulation of prelamin A and cell senescence, serial passaging of primary human VSMCs was performed in vitro. Consistently, the VSMC proliferation rate abruptly declined in the 1 to 2 passages ( Figure 2A ; Online Figure II ) before senescence. Importantly, VSMCs in this presenescent phase showed prelamin A accumulation; however, the cells remained proliferative, and only a small percentage was positive for senescence-associated β-galactosidase. This contrasted with senescent VSMCs, which ceased proliferation, exhibited a flattened and enlarged appearance, were positive for senescence-associated β-galactosidase activity, and showed highly elevated levels of prelamin A ( Figure 2B and 2C).
Importantly, real-time quantitative reverse transcription-polymerase chain reaction analysis revealed that the mRNA levels of the osteogenic markers Runx2, ALP, and osteocalcin were also increased during this presenescent phase, coinciding with prelamin A accumulation, and were subsequently decreased at senescence ( Figure 2D ). Moreover, concomitant with changes in VSMC growth capacity, the mRNA levels of the cyclin-dependent kinase inhibitors p16 and p21 also increased with a marked increase in p16 expression in presenescent VSMCs and a dramatic 50-fold increase when the cells reached senescence ( Figure 2E ). In contrast, p21 mRNA levels were elevated only at senescence and to a much lesser extent. Similarly, adenoviral expression of prelamin A in early-passage VSMCs was found to induce p16 expression but had little effect on either p21 levels or p53 phosphorylation, suggesting that presenescent VSMCs with prelamin A accumulation and elevated levels of p16 may be culprits in inducing VSMC calcification ( Figure 2F ).
Prelamin A Accelerates VSMC Mineralization and Promotes Osteogenic Differentiation
The above findings led us to investigate whether prelamin A accumulation could facilitate VSMC mineralization in vitro. As shown in Figure 3A , adenoviral expression of prelamin A in early-passage VSMCs for 3 days induced a hills-and-valleys morphology compared with control virus. Moreover, when VSMCs were cultured in osteogenic media to induce mineralization, adenoviral expression of prelamin A significantly increased mineral deposition compared with control, shown by Alizarin red staining, and 45 Ca incorporation ( Figure 3A and 3B). This was associated with upregulated mRNA levels of a panel of bone-related genes, including Runx2, bone morphogenetic protein 2 (BMP2), ALP, and osteocalcin ( Figure 3C ). Increased osteogenic differentiation was confirmed at the protein level as increased ALP activity and elevated Runx2 on Western blot ( Figure 3D and 3E). Prelamin A had no effect on VSMC matrix vesicle release, and inhibition of ALP activity with levamisole significantly decreased calcification, confirming that prelamin A drives calcification by promoting increased osteogenic differentiation ( Figure 3E ; Online Figure III ).
Microarray Analysis Reveals Prelamin A Downregulates DNA Damage Repair Pathways in VSMCs
To gain insights into the mechanisms whereby prelamin A promotes osteogenic differentiation of VSMCs, we performed microarray analysis comparing early-passage VSMCs infected with control or prelamin A adenovirus. After array normalization, 20 254 gene expression profiles were reduced to 2 principal components. The separation of control and treated VSMCs in the principal component space ( Figure 4A ) confirmed that these cell populations had distinct gene expression profiles. Subsequently, expression profiles of 10 127 genes that passed our quality control threshold (across-array expression variance in the top 50th percentile) were assessed for differential expression. Overall, there were 3052 significantly regulated genes (adjusted P<0.05), of which 1301 and 1751 were upregulated and downregulated, respectively ( Figure 4B ). Among them, there was a group of genes involved in ossification and mineralization, including osteopontin and Runx2 (Online Table II ).
In addition, activity assessment of 459 biological pathways captured by all differentially expressed genes revealed both upregulated and downregulated pathways. Upregulated pathways included hypertrophic cardiomyopathy and lipid metabolism, which are known to be affected by nuclear lamina deregulation. 32 Of the downregulated pathways identified, one third were involved in DNA damage repair, suggesting that the DDR was the most represented pathway (Online Table  III ). 33 Analysis of the Biocarta Database revealed that the most downregulated signaling pathway was the telomeres pathway, which plays a role in cellular aging, as well as the ataxia-telangiectasia-mutated (ATM) pathway, a key regulator of the DDR ( Figure 4C ; Online Table IIIA) .
Consistent with this array analysis and previous studies, 4 overexpression of prelamin A in early-passage VSMCs was found to exaggerate the extent of DNA damage shown by increased phosphorylation of H2AX and increased ATM/ ataxia-telangiectasia-and Rad3-related (ATR) signaling ( Figure 5A ). In addition, prelamin A expression caused an increase in the number of VSMCs exhibiting 3 or more 53BP1 foci per nucleus, an indicator of persistent (ie, unrepairable) DNA damage ( Figure 5B ). 34 Moreover, VSMCs, induced to calcify with osteogenic media, also showed increased prelamin A accumulation and increased levels of DNA damage ( Figure 5C ; Online Figure IVA ), similar to the accumulation observed when VSMCs were treated with hydrogen peroxide, a known DNA-damaging agent (Online Figure IVB ), suggesting that there may be a close association between DNA damage signaling and VSMC osteogenic differentiation.
DNA Damage Repair Signaling Promotes VSMC Osteogenic Differentiation and Mineralization
To test the role of DNA damage signaling in promoting osteogenic differentiation, VSMCs were treated with the ATM/ATR . Prelamin A was found at a nuclear pole in <10% of VSMCs in vessels from healthy children. In vessels from children on dialysis, prelamin A was heavily deposited in association with degenerate VSMCs (arrow). von Kossa staining shown in the lower panel demonstrated the absence of calcification in controls, whereas dialysis vessel showed medial calcification (arrow). B, Quantification showed a significant increase in prelamin A-positive VSMCs in arteries from children on dialysis (n=5) compared with controls (n=5). Unpaired t test. C, Immunofluorescence showing accumulation of nuclear prelamin A (C20) in nodular (delineated by dotted line) VSMCs. Arrow indicates monolayer VSMCs negative for prelamin A. D, VSMCs were cultured in normal media and harvested at 80% confluence (proliferating) or cultured in osteogenic media for 2 weeks before separation of monolayer and nodular cells. Prelamin A identified using anti-lamin A/C (N18) was detectable only in mineralized VSMCs and was abundant in the nodular fraction. αActin was decreased in nodular VSMCs, consistent with mineralization. βActin shows equal loading. E and F, Senescenceassociated βgalactosidase activity staining shows that many nodular VSMCs (arrow) are senescent compared with confluent monolayer cells from the same culture, consistent with Western blot showing increased levels of p16 expression in nodular VSMCs. βActin is the loading control. DAPI indicates 4',6diamidino2phenylindole.
inhibitor CGK733 or Ku55933, a specific ATM inhibitor, and induced to calcify in osteogenic media. Both inhibitors efficiently blocked VSMC mineralization and attenuated the VSMC morphology changes induced by prelamin A overexpression ( Figure 6A ; Online Figure V ). Importantly, inhibition of ATM/ ATR signaling decreased expression of p16 in VSMCs and was associated with dramatic reductions in both endogenous and prelamin A-induced mRNA levels of the bone markers Runx2, ALP, and osteocalcin ( Figure 6B-6D) , consistent with the notion that DNA damage signaling is upstream of both VSMC osteogenic differentiation and p16-induced senescence. 35 
Prelamin A and DNA Damage Signaling Induce VSMC Osteogenic Differentiation Via Increased Secretion of Paracrine Factors
It is well recognized that cells approaching senescence develop a senescence-associated secretory phenotype (SASP), which can be triggered by persistent DNA damage signaling. 34 Therefore, we tested whether prelamin A induced paracrine osteogenic signals in VSMCs using a coculture system in which VSMCs infected with either adenovirus vector encoding enhanced green fluorescent protein (AdEGFP) or AdPrelamin A were seeded with C 2 C 12 mesenchymal precursors. C 2 C 12 cells cocultured with VSMCs overexpressing prelamin A showed a significant increase in ALP activity compared with controls ( Figure 7A ). To determine whether these paracrine effects could be inhibited by blocking DNA damage signaling, AdEGFP-or AdPrelamin A-infected VSMCs were subjected to siRNA knockdown of ATM or ATR (Online Figure VI) and then cocultured with C 2 C 12 . After 5 days of coculture, the ALP activity in C 2 C 12 cells was significantly blocked by ATM depletion in VSMCs. ATR depletion was also effective; however, it was also associated with ATM depletion in prelamin A-overexpressing VSMCs, suggesting that ATM was the most potent transducer of this pathway ( Figure 7B ).
Prelamin A Promotes Induction of the SASP in VSMCs
To further interrogate the secreted factors involved in driving osteogenic differentiation, we used human cytokine arrays to compare the cytokine profile of VSMCs expressing prelamin A with controls (Online Figure VII) . Of the 120 secreted factors tested, 18 previously recognized SASP factors were abundantly secreted by prelamin A-expressing VSMCs and could be subgrouped into inflammatory factors, growth factors, soluble or shed receptors/ligands, and proteases involved in extracellular matrix remodeling (Table) . 36 This analysis also revealed an additional 24 less abundantly secreted cytokines regulated by prelamin A overexpression, including BMPs and interleukins (ILs; Online Table IV ). Using ELISA, we validated increased secretion by VSMCs expressing prelamin A of IL6, the most abundant cytokine secreted by VSMCs, as well as BMP2 and osteoprotegerin, all proteins previously implicated in the regulation of VSMC calcification ( Figure 7C ). 31, 37 Passage number Importantly, quantitative reverse transcription-polymerase chain reaction analysis showed that the mRNA levels of these cytokines ( Figure 7D ) were increased in presenescent VSMCs during serial passaging in vitro but markedly decreased when VSMCs reached senescence, a pattern mirroring that observed for osteogenic differentiation markers and p16. Quantitative reverse transcription-polymerase chain reaction analysis of abundant cytokines and further array analysis comparing VSMCs treated with or without CGK733 revealed that the expression of many of these cytokines, including IL6, BMP2, and osteoprotegerin, was regulated by ATM/ATR signaling ( Figure 7E ; Online Figure VIII) . However, several cytokines were not regulated by DNA damage signaling, suggesting that prelamin A may also activate other pathways that promote VSMC inflammation and calcification independently of the DDR (Online Table V ).
Discussion
In this study, we identify DNA damage signaling as a key mediator of VSMC osteogenic differentiation and demonstrate that the accumulation of prelamin A in presenescent VSMCs amplifies this pathway to accelerate calcification. We show that ATM signaling acts upstream of both osteogenic differentiation and the induction of the SASP and release of potent calcification promoting factors such as BMP2 from VSMCs, which may drive calcification both locally and at remote sites. Importantly, we provide evidence that this pathway is clinically relevant by showing deposition of prelamin A in calcified arterial biopsy samples from children on dialysis. Taken together, these data suggest that the DDR may be a crucial signaling pathway driving age-associated vascular pathologies, making it a key therapeutic target for blocking progression of vascular calcification in a variety of clinical conditions. 38
Prelamin A-Induced Amplification of the DDR Is a Potent Driver of VSMC Mineralization
We showed that prelamin A accumulates in calcifying VSMCs both in vitro and in vivo. It was first detectable in presenescent VSMCs, and its accumulation occurred concomitantly with upregulation of the cyclin-dependent kinase inhibitor p16 and increased expression of key osteogenic proteins, including Runx2. Adenoviral expression of prelamin A increased p16 and VSMC osteogenic differentiation and mineralization and exacerbated DNA damage signaling, suggesting a causal relationship. The link between VSMC osteogenic differentiation and DNA damage was confirmed in studies showing that inhibition of the DDR, using chemical or siRNA-mediated knockdown of ATM signaling, inhibited p16 upregulation and completely abrogated osteogenic differentiation and mineralization of VSMCs and C 2 C 12 cells. 39 Thus, these data provide for the first time evidence of direct causality between the accrual of DNA damage in the diseased vessel wall and the induction of an age-associated vascular pathology, that is, calcification.
Our data suggested that increased VSMC osteogenic differentiation in response to DNA damage may be induced primarily via activation of the SASP. Indeed, we showed that knockdown of ATM signaling reduced the osteogenic capacity of VSMCs, and this was associated with decreased secretion of osteogenic and inflammatory cytokines such as BMP2 and IL6, shown to have roles in promoting vascular Figure 3 . Prelamin A accumulation promotes vascular smooth muscle cell (VSMC) calcification. A, VSMCs infected with AdPrelamin A, but not control virus, for 3 days formed hills andvalleys (arrow) and showed increased matrix mineral deposition in response to osteogenic media shown by Alizarin red staining. B, Quantification using 45 Ca shows a significant increase in calcium incorporation in prelamin A overexpressing VSMCs (n=3). C, Quantitative reverse transcriptionpolymerase chain reaction shows that overexpression of prelamin A significantly increased expression of the bonerelated genes encoding Runx2, bone morphogenetic protein 2, alkaline phosphatase (ALP), and osteocalcin (n=6 37, 40 However, studies in bone suggest that the DDR may also directly affect expression and regulation of key osteogenic transcription factors. ATM -/mice show decreased bone formation, and it has been shown that ATM signaling has cell-autonomous effects on osteoblast differentiation and can enhance BMP2 signaling to promote expression of the essential osteogenic transcription factor osterix, which acts downstream of Runx2. 41 Runx2 itself has been shown to bind the DDR proteins Ku70 and Ku80, leading to increased expression of osteocalcin, suggesting that in response to DNA damage, Runx2 may also be activated. 42 p53 also acts as a key signaling hub linking DNA damage signaling and osteogenic differentiation. 43 Although we did not see changes in p53 phosphorylation in response to prelamin A accumulation in this study, regulation of these signaling pathways is likely to be cell context dependent, and further experimentation is required to test their role in VSMC model systems.
Previous studies have implicated prelamin A in the amplification of DNA damage, 33 and experiments in fibroblasts from zinc metallopeptidase STE24 homolog -/animals, which are deficient for the lamin A processing enzyme, have shown that prelamin A acts to delay the recruitment of 53BP1, a key DNA damage mediator, to sites of double-strand breaks. 21 In addition, our microarray analysis in VSMCs revealed that prelamin A accumulation downregulated several upstream DNA damage sensors and downstream mediators in the ATM pathway such as BRCA1, RAD50, MRE11A, and GADD45A, which play essential roles in homologous and nonhomologous recombination-mediated DNA double-strand break repair, providing further insights into the mechanisms whereby nuclear lamina dysfunction can affect DNA damage repair. Our studies also indicated that the induction by prelamin A of persistent DNA damage signaling and ultimately the SASP may be one mechanism whereby nuclear lamina disruption drives VSMC osteogenic differentiation. However, there is evidence to suggest that prelamin A may also promote calcification via DDR-independent mechanisms. VSMC osteogenic differentiation proceeds through several pathways, including, Notch, BMP, and Wnt signaling, and array analysis has shown that progerin, the truncated form of prelamin A, expressed in patients with HGPS, acts to enhance the osteogenic differentiation of human mesenchymal stem cells via activation of the Notch signaling pathway. 44 Other studies have also implicated progerin in the regulation of VSMC matrix production, Wnt signaling, and survival in response to hypoxia. 20 Similarly, our microarray analysis also identified changes in nuclear factor-κB, insulin-like growth factor-1, mitogen-activated protein kinase, Akt, and Wnt pathways in response to prelamin A accumulation in VSMCs. Thus, it is likely that prelamin A may enhance osteogenic signaling in VSMCs via additional pathways that may act in combination with DNA damage to exacerbate calcification.
Persistent DNA Damage Triggers a VSMC-Specific SASP, Which Links VSMC Osteogenic Differentiation With Aging
Extensive studies have shown that cells with persistent DNA damage and elevated levels of p16 develop a specific SASP. Previously identified SASP factors such as IL1β, IL6, IL8, monocyte chemoattractant protein 1, osteoprotegerin, and intracellular adhesion molecule-1 were abundantly secreted by VSMCs in response to prelamin A-induced persistent DNA damage, as well as other potential VSMC-specific SASP factors such as BMPs that have not been identified in other cell types. 36 Importantly, elevated BMP2 levels have been reported in adults with chronic kidney disease correlating with arterial stiffening, whereas elevated levels of IL6, the most abundant cytokine secreted by VSMCs, correlate with vascular dysfunction in aged animal models and aged humans. [45] [46] [47] In addition, numerous studies have shown that circulating levels of osteoprotegerin are elevated in patients with calcified arteries. 48 Taken together, these studies raise the possibility that arterial aging pathologies may be driven by the SASP and that the damaged vasculature may serve as a major source of inflammatory cytokines. This notion is also supported by numerous studies showing elevated levels of prelamin A, DNA damage, and p16-positive senescent VSMCs in the diseased vessel wall. 49, 50 Clearly, the influence that these SASP factors have on vascular cell phenotypes, particularly resident stem cells, and potentially other tissues such as bone, which apparently demineralizes as vascular calcification increases, requires further investigation. 51 Ad EGFP 
Prelamin A Is a Major Factor Driving Vascular Aging
This study showed that prelamin A markedly accelerated VSMC aging; however, the mechanisms driving prelamin A accumulation in VSMCs remain poorly understood. Previous studies have shown that farnesylated proteins-converting enzyme 1/zinc metallopeptidase STE24 homolog expression is downregulated in response to both replicative senescence and oxidative stress, and consistent with this, in this study, we showed that both these factors promoted prelamin A accumulation in VSMCs. 4 It is likely that these mechanisms also drive prelamin A accumulation in vivo. In the context of aging and atherosclerotic calcification, telomere shortening and replicative senescence of VSMCs have been documented. 52 In addition, VSMCs may also undergo stress-induced premature senescence because of exposure to factors such as oxidative stress in the absence of critical telomere shortening. 52 This second mechanism may also explain the observation of prelamin A deposition in the prematurely aged arteries of children on dialysis. 30 In this context, it is likely that increased oxidative stress leads to prelamin A accumulation and stress-induced premature senescence in nonreplicating VSMCs. Dysregulated mineral metabolism has emerged as the most potent driver of vascular calcification in patients on dialysis, and we observed increased prelamin A accumulation and DNA damage in VSMCs treated with media supplemented with Ca and Pi. These data suggest that Ca/Pi may induce oxidative stress in VSMCs, and emerging evidence supports this notion. 53 Additionally, other uremic toxins such as indoxyl sulfate also promote oxidative stress in VSMCs, so there may Figure 7 . Prelamin A induces pro-osteogenic cytokine secretion by vascular smooth muscle cells (VSMCs). A, Alkaline phoshate (ALP) activity of C 2 C 12 cells cocultured with earlypassage VSMCs overexpressing prelamin A was significantly increased compared with control (n=6). Paired t test. B, Treatment of VSMCs with ataxiatelangiectasiamutated (ATM) or ataxiatelangiectasia-and Rad3related (ATR) RNAi significantly blocked ALP activity in C 2 C 12 cells cocultured with prelamin A-overexpressing VSMCs. ANOVA and Newman Keuls multiplecomparison test (n=6). C, ELISA assay confirmed that bone morphogenetic protein 2 (BMP2), osteoprotegerin (OPG), and interleukin (IL) 6 levels were significantly increased in conditioned media from VSMCs infected with AdPrelamin A. Paired t test (n=3). D, Quantitative reverse transcription-polymerase chain reaction (RTPCR) showed that CGK733 significantly blocked endogenous and prelamin A-induced expression of BMP2, OPG, and IL6. ANOVA and Newman Keuls multiplecomparison test (n=3). E, RTPCR shows that BMP2, OPG, and IL6 mRNA levels were increased in presenescent prelamin A-positive VSMCs, mirroring increased p16 and osteogenic differentiation (n=3). EGFP indicates enhanced green fluorescent protein. ENA78 indicates epithelial neutrophil-activating protein 78; GCP-2, granulocyte chemotactic protein-2; GRO/α, growth-related oncogene/α; IGFBP-4/6, insulin-like growth factor-binding proteins 4/6; IL6/8, interleukin 6/8; MCP-1/2/3, monocyte chemoattractant protein 1/2/3; OPG, osteoprotegerin; SASP, senescence-associated secretory phenotype; TIMP-1/2, tissue inhibitor of metalloproteinases-1/2; uPAR, urokinase plasminogen activator receptor; VEGF, vascular endothelial growth factor; and VSMC, vascular smooth muscle cell. Cytokine array was applied to 4 samples infected with either AdPrelamin A or adenovirus vector encoding enhanced green fluorescent protein (AdEGFP). Of 120 cytokines, 18 cytokines were found to be abundantly secreted by VSMCs, subgrouped into 4 categories as shown.
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be several factors that contribute to prelamin A accumulation in the uremic milieu. 54 Because oxidative stress can also induce DNA damage, it is likely that concomitant induction of DNA damage and prelamin A accumulation will promote a vicious cycle of persistent DNA damage signaling, osteogenic differentiation, inflammation, and ultimately senescence. 55 Whether antiaging factors specific to the uremic milieu such as Klotho also decrease in VSMCs under these same conditions will be important to explore. 56 Finally, animal studies have shown that drugs such as statins, bisphosphonates, and rapamycin can ameliorate some of the toxic effects of prelamin A accumulation, and there are ongoing clinical trials to test these agents in patients with HGPS. 57, 58 In addition, this study suggests that drugs that target DNA damage signaling, which are currently also in trials for cancer therapy, may represent potential therapies for age-related vascular decline. 59
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